Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Elanco-Bayer Deal Receives FTC Approval

Wednesday, July 15, 2020 12:25 PM EDT
By Alex Brown
Elanco-Bayer Deal Receives FTC Approval (IIB Photo/Alex Brown)

The Federal Trade Commission has unanimously approved Greenfield-based Elanco Animal Health Inc.’s (NYSE: ELAN) proposed $7.6 billion acquisition of Bayer Animal Health. Elanco says the approval is the final antitrust clearance it needed to close the deal, which is expected to take place in August.

Bayer Animal Health is a subsidiary of Germany-based Bayer AG. The FTC approval comes just over a month after the deal received approval from the European Commission.

“This approval marks the near-final step in fulfilling our vision of bringing together two dedicated animal health companies focused on delivering innovation and an expanded portfolio of solutions to farmers, veterinarians and pet owners around the globe,” Jeff Simmons, president chief executive officer of Elanco, said in a news release. “As we approach closing and look toward putting our integration plans into action, I want to thank everyone who has worked so tirelessly on this transaction, especially during these challenging times.”

The FTC approval comes with conditions that Elanco must make certain divestitures, which the company says would be in the range of $120 million to $140 million of annual revenue. 

The proposed divestitures include:

  • Worldwide rights for Elanco’s Osurnia, a treatment for otitis externa in dogs, being sold to Dechra Pharmaceuticals PLC.
  • U.S. rights for Elanco’s Capstar, an oral tablet that kills fleas in dogs and cats, being sold to PetIQ, Inc. (Nasdaq: PETQ).
  • U.S. rights for Elanco’s StandGuard, a pour-on treatment for horn fly and lice control in beef cattle, being sold to Neogen Corp. (Nasdaq: NEOG).

The acquisition also previously received antitrust clearance in Australia, Brazil, Canada, China, Colombia, New Zealand, South Africa, Turkey, Ukraine, and Vietnam.

When the deal is complete, Elanco says it will become the second-largest animal health company by revenue.

Story Continues Below

Most Popular Stories

  • Armstrong named next CEO of Child Advocates

  • Notre Dame buys former South Bend Tribune offices

  • NCAA President calls for new D-I tier where schools can pay athletes

  • Indiana United Ways to award $80M for capital projects

  • Workforce shuttles drop fares to Plainfield, Whitestown

  • Q&A with IU South Bend Associate Dean of Nursing Barbara White

Perspectives

Grow your business: Learn from failure

Grow your business: Learn from failure

Basketball phenom Steph Curry of the Golden State Warriors is no stranger to losing, much less failure, even though he is one of the most successful professional basketball players of today. His record-breaking career has had countless ups and downs....

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service